ulcerex 20 mg gél. gastro-résist.
aristo pharma gmbh - esoméprazole magnésien dihydraté 21,69 mg - eq. esoméprazole 20 mg - gélule gastro-résistante - 20 mg - esoméprazole magnésien dihydraté 21.69 mg - esomeprazole
ulcerex 40 mg gél. gastro-résist.
aristo pharma gmbh - esoméprazole magnésien dihydraté 43,38 mg - eq. esoméprazole 40 mg - gélule gastro-résistante - 40 mg - esoméprazole magnésien dihydraté 43.38 mg - esomeprazole
ulcerex 20 mg gél. gastro-résist.
aristo pharma gmbh - esoméprazole magnésien dihydraté 21,69 mg - eq. esoméprazole 20 mg - gélule gastro-résistante - esomeprazole
ulcerex 40 mg gél. gastro-résist.
aristo pharma gmbh - esoméprazole magnésien dihydraté 43,38 mg - eq. esoméprazole 40 mg - gélule gastro-résistante - esomeprazole
soliris solution
alexion pharma gmbh - Éculizumab - solution - 10mg - Éculizumab 10mg - complement inhibitors
takhzyro
takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedèmes, héréditaires - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.
ultomiris solution
alexion pharma gmbh - ravulizumab - solution - 10mg - ravulizumab 10mg - immunosuppressive agents
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - tous les autres produits thérapeutiques - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
ultomiris solution
alexion pharma gmbh - ravulizumab - solution - 300mg - ravulizumab 300mg
ultomiris solution
alexion pharma gmbh - ravulizumab - solution - 1100mg - ravulizumab 1100mg